Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

726 results about "Hyperinflammatory disorder" patented technology

Multifunctional proteolysis-targeting chimera conjugates

The present invention relates to various molecular constructs having at least one cellular-targeting element, one protein-targeting element, and one ubiquitin ligase recruitment element, wherein these elements are conjugated in a manner that facilitates cellular uptake and targeted degradation of specific proteins within cells. The present invention further relates to multifunctional proteolysis-targeting chimera conjugates and uses thereof for the treatment of diseases or disorders such as immune and inflammatory diseases, infectious diseases, cardiovascular diseases, endocrine disorders, and various cancers that are otherwise resistant to traditional therapeutic regimens.
Owner:BIOXEL INC

Dual cytokine fusion proteins comprising IL-10

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and / or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
Owner:IOVANCE BIOTHERAPEUTICS INC

Heterocyclic derivatives and use thereof in medicine

The present invention relates to heterocyclic derivatives and the use thereof in medicine, in particular to compounds represented by general formula (I) or stereoisomers, pharmaceutically acceptable salts or cocrystals and intermediates thereof, a preparation method therefor, and the use thereof in the preparation of drugs for treating autoimmune diseases or inflammatory diseases.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

Antibodies that bind TSLP and methods of use

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.
Owner:PARAGON THERAPEUTICS INC

Antibodies with FC modifications and methods of using the same

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
Owner:THE GENERAL HOSPITAL CORP

Inhibitors of canine janus kinase and uses thereof

PCT designated stage expiredWO2024246837A1Organic chemistryAntipyreticAtopic dermatitisJanus kinase
Provided herein are compounds having inhibitory activity toward the Janus Kinase 1 (JAK-1) enzyme, and which are useful as therapeutic and / or prophylactic agents. The compounds may be useful in treating inflammatory disorders in non-human mammals, for example, in treating canine atopic dermatitis. Also provided herein are methods for preparation of such compounds.
Owner:ANIMOL DISCOVERY

Inhibitors of RIPK2 and uses thereof

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I') or (X"): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.
Owner:ODYSSEY THERAPEUTICS INC

Single domain antibodies for inhibiting neutrophil elastase activity

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.
Owner:UNIV LIEGE +2

Modified tetracycline for treatment of alcohol use disorder, pain and other disorders involving potential inflammatory processes

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.
Owner:TEXAS TECH UNIV SYST

(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
Owner:PHARVARIS GMBH

Novel compounds

The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder:wherein RA, RB, RC and RD, X, m and n are as defined herein.
Owner:SITRYX THERAPEUTICS LTD

Compositions and methods comprising combinations of TSLP and ox40l antibodies

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and OX40L in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-OX40L antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or OX40L.
Owner:PARAGON THERAPEUTICS INC

Non-ATP / catalytic site p38 mitogen activated protein kinase inhibitors

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
Owner:UNIV OF MARYLAND

Treatment of autoimmune or inflammatory disease

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.
Owner:FORWARD THERAPEUTICS INC

NOVEL ADIPONECTIN-DERIVED PEPTIDE DERIVATIVE AND ITS USE

The present invention relates to a novel peptide derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptide derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.
Owner:SEOUL NAT UNIV HOSPITAL +1

Dosage regimens for the treatment of autoimmune and inflammatory diseases using ly3871801

Disclosed herein are methods of treating a subject having an autoimmune or inflammatory disease, and formulations associated therewith, comprising administering to the patient a compound of (S)-5-benzyl-N-(7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered at a dose of about 12.5 mg to about 125 mg free base equivalent of said compound per dose.
Owner:ELI LILLY & CO +1

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Owner:PHARMACYCLICS LLC

Formulations and dosing regimens for rip1 kinase inhibitors for treating autoimmune and inflammatory diseases

Disclosed herein are methods of treating a subject having an autoimmune or inflammatory disease, and formulations associated therewith, comprising administering to the patient a compound of(S)-5-benzyl-N-(7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered at a dose of about 12.5 mg to about 125 mg free base equivalent of said compound per dose.
Owner:ELI LILLY & CO +1

Inhibitors of TYK2

In exemplary embodiments, inhibitors of Tyrosine Kinase 2 (TYK2), pharmaceutical formulations comprising these compounds, methods of using these compounds to inhibit TYK2, and treat diseases such as autoimmune and inflammatory diseases are provided.
Owner:ATOMWISE INC

Small molecule IL-17A modulators

Disclosed herein are fused bicyclic compounds useful as modulators of small molecule IL-17A. Disclosed herein are the use of these small molecule IL-17A modulators for lowering IL-17 activity by inhibition, and the use of such compounds for the treatment of autoimmune or inflammatory diseases.
Owner:BEIGENE (SUZHOU) CO., LTD.